People who report having palpitations appear to have an increased risk of being diagnosed with atrial fibrillation in the future, a Norwegian study showed. Self-reported palpitations were associated with incident atrial fibrillation over an average of 11 years of follow-up in both women (HR 1.62, 95% CI 1.29 to 2.02) and men (HR 1.91, 95% CI 1.54 to 2.35), according to Audhild Nyrnes, MD, of the University of Tromsø in Norway, and colleagues.
Washington, D.C., May 15, 2012 — American Heart Association CEO Nancy Brown issued the following comments on today’s recommendation by the Community Preventive Services Task Force on team-based care and hypertension: “As a proud and committed partner in the Million Hearts initiative, the American Heart Association commends the Community Preventive Services Task Force for recommending team-based care to improve blood pressure control
St. Jude Medical, Inc. (NYSE:STJ ), a global medical device company, today announced it will display a number of technologies from the company s wide array of clinical solutions and launch its next-generation PressureWire™ Fractional Flow Reserve (FFR) assessment guidewire at EuroPCR 2012. There will also be a number of St. Jude Medical-sponsored percutaneous coronary intervention (PCI) optimization symposia and a late-breaking clinical trial session on the FAME II trial.
Boston Scientific Corporation (NYSE: BSX) and Royal Philips Electronics (NYSE: PHG, AEX: PHI) announced a collaboration enabling Philips to sell Boston Scientific Imaging equipment in connection with its Allura Xper catheterization (cath) lab systems in territories throughout the world.
STENTYS S.A. (STNT.PA), a medical technology company commercializing the world s first and only Self-Apposing® Stent to treat Acute Myocardial Infarction (AMI), announced today that it is launching a thrombectomy device (aspiration catheter) called STENTYS AC.
Interventional cardiology is usually associated with stents, balloons, catheters and an array of niche devices that can shave, vacuum, and compress the plaque or thrombus that blocks arteries, causes ischemia and heart attacks. But a relatively new and rapidly growing area in intervention is called Intravascular Imaging and Guidance. Ultrasound, lasers, and thin wires that measure flow velocity and blood pressure are increasingly being used by cardiologists -- first, to help decide whether or not to stent a coronary artery and second, to yield information that makes placing and sizing those stents more accurate and safer.
Destacó la Sociedad Española de Cardiología con motivo de la celebración, el pasado domingo, del Día de la Madre, haciéndose eco de la publicación de diversos estudios que así lo señalan.
Cardionovum has announced that it will launch two drug-eluting balloon (DEB) dilatation catheter product families at EuroPCR 2012 congress (Paris, France, 15–18 May): Paclitaxel-coated drug-eluting balloons for coronary (Primus) and peripheral (Legflow) applications.
Boston Scientific Corporation (BSX) announces results from the ASA Plavix (ASAP) Study, which studied the WATCHMAN® Left Atrial Appendage Closure (LAAC) device. The data showed a reduction in the risk of ischemic stroke by 75 percent in patients with atrial fibrillation who have a contraindication to oral anticoagulants such as warfarin. Vivek Reddy, M.D., Director of Cardiac Arrhythmia Service at Mount Sinai Medical Center in New York and Coordinating Investigator of the study presented results today during a late-breaking session at the Heart Rhythm Society s 33rd Annual Scientific Sessions in Boston.
BIOTRONIK, Inc., announced today the U.S. launch of its new Reocor external pacemaker. The device is available in two models, for dual- and single-chamber pacing therapy, and offers individualized patient therapy, easy handling and flexibility in every detail. Reocor enriches BIOTRONIK’s portfolio of high quality cardiovascular devices and sets a new standard of quality for external pacing therapy.
Medtronic, Inc. (NYSE: MDT ) today announced findings from an economic analysis of the landmark RAFT (Resynchronization / Defibrillation in Ambulatory Heart Failure Trial) trial demonstrating that cardiac resynchronization therapy with defibrillation (CRT-D) is a cost-effective treatment for mildly symptomatic heart failure patients. The findings showed a $33,025 (USD) cost per Quality Adjusted Life Year (QALY) gained using Medtronic CRT-Ds in a mild, New York Heart Association (NYHA)-designated Class II-III heart failure patient population, substantially lower than the benchmark for therapy cost effectiveness of other serious chronic conditions that cost at least $50,000 per QALY gained.1 QALY is a measure of the quantity and quality of life.
Loma Vista Medical has announced that it has received CE mark for its True Dilatation Balloon Valvuloplasty Catheter and will be launching its initial product at EuroPCR (Paris, France, 15–18 May 2012).
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced results of the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial) 10-Year Follow-up Study at Heart Rhythm 2012, the Heart Rhythm Society s 33rd Annual Scientific Sessions in Boston. The study demonstrated implantable cardioverter defibrillator (ICD) therapy significantly reduces mortality for at least 11 years in patients with moderate heart failure (HF).
BIOTRONIK, a leading manufacturer of innovative medical technology, has received FDA approval of its new Lumax 740 implantable cardioverter defibrillators (ICDs) and cardiac resynchronization therapy devices (CRT-Ds). Lumax 740 helps physicians monitor and treat their patients’ arrhythmias and heart failure under ever-changing medical conditions.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos